ACX-02
Alzheimer's Disease / Neurodegeneration
Pre-clinicalActive
Key Facts
Indication
Alzheimer's Disease / Neurodegeneration
Phase
Pre-clinical
Status
Active
Company
About Applied Cognition
Applied Cognition is pioneering a novel therapeutic approach focused on enhancing the brain's glymphatic waste clearance system to treat neurodegenerative diseases. Its core asset is a proprietary, non-invasive measurement platform that has identified targets and led to a lead small molecule combination candidate, ACX-02, which has shown early biomarker evidence of clearing amyloid and tau. The company is leveraging its platform for ongoing target discovery and drug development, positioning itself at the intersection of neuroscience, physiology, and potential AI-driven insights.
View full company profileTherapeutic Areas
Other Alzheimer's Disease / Neurodegeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| SCP Platform | Lateral Pharma | Preclinical |